These observations are most relevant to human cancers that develop diverse mechanisms to dysregulate EGFR signaling, including overexpression of receptors and overproduction of ligands, resulting in a resistance to signaling inhibition by targeted drugs60–62. This evidence concerns the gene EGFR and cancer.